Form 4: Vaxcyte CFO Andrew Guggenhime Executes Stock Option and Sells Shares Under 10b5-1 Plan

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 18, 2024, Andrew Guggenhime, the President and CFO of Vaxcyte, Inc., exercised stock options to acquire 8,000 shares of common stock at a price of $5.35 per share.
• Simultaneously, Guggenhime sold 7,624 shares at a weighted average price of $61.244, with prices ranging from $60.83 to $61.77.
• He also sold 376 shares at a weighted average price of $61.902, with prices ranging from $61.85 to $62.15.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 30, 2023.
• Following these transactions, Guggenhime directly owns 95,679 shares of Vaxcyte common stock and 360,827 stock options.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment about the company's prospects. The transactions are part of a pre-arranged plan.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on non-public information. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.

Key Dates